USFDA issues waring letter to Lupin’s Goa, Indore plants

The US Food and Drug Administration (FDA) has issued a warning letter to Lupin for violation of current good manufaturing practice norms at two of its manufacturing facilities in Goa and Indore.
In a letter to Lupin managing Director Nilesh Gupta, USFDA said inspectors during inspection from March 27 to April 7, found significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals.